Third Harmonic Bio Inc THRD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if THRD is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $10.46
- Day Range
- $10.27–10.97
- 52-Week Range
- $4.31–12.42
- Bid/Ask
- $11.00 / $17.31
- Market Cap
- $441.40 Mil
- Volume/Avg
- 75,810 / 153,113
Key Statistics
- Price/Earnings (Normalized)
- 11.39
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company’s product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 30
- Website
- https://www.thirdharmonicbio.com
Comparables
Valuation
|
Metric
|
THRD
|
EWTX
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.39 | — | — |
Price/Book Value | 1.61 | 3.57 | 12.65 |
Price/Sales | — | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
THRD
EWTX
CBAY
Financial Strength
|
Metric
|
THRD
|
EWTX
|
CBAY
|
|---|---|---|---|
Quick Ratio | 49.66 | 18.98 | 10.70 |
Current Ratio | 50.29 | 19.50 | 10.96 |
Interest Coverage | — | — | −5.27 |
Quick Ratio
THRD
EWTX
CBAY
Profitability
|
Metric
|
THRD
|
EWTX
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −7.40% | −24.36% | −30.06% |
Return on Equity (Normalized) | −7.63% | −25.87% | −51.97% |
Return on Invested Capital (Normalized) | −12.16% | −29.82% | −30.87% |
Return on Assets
THRD
EWTX
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pnqrddppc | Btp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lpybhbbt | Mqhtjx | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jsxdtkzbl | Qmqhnj | $97.8 Bil | |
MRNA
| Moderna Inc | Ljqbggzy | Frtq | $41.3 Bil | |
ARGX
| argenx SE ADR | Hbcnmbvpy | Bhc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lvbplbc | Ylwq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kvqdymz | Bfqgpnv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tqyydyxn | Rhxzlr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tjscmpxg | Whtdjx | $12.5 Bil | |
INCY
| Incyte Corp | Bmgvhkr | Xmstzq | $11.6 Bil |